Using this protocol, NY-ESO-1-specific CD8+ T cells were frequently detected from NY-ESO-1 seropositive ovarian cancer patients but not from healthy individuals in this study cohort (Figure S1(A)). Here, CD8A is linked to ovarian carcinoma.